Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORTNYSE:BKDNASDAQ:CNTANASDAQ:KURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$30.30+2.0%$27.21$21.97▼$32.33$1.27B1.62338,729 shs549,608 shsBKDBrookdale Senior Living$6.83-0.2%$6.58$4.45▼$8.12$1.60B0.812.53 million shs6.62 million shsCNTACentessa Pharmaceuticals$12.43-2.0%$12.70$8.46▼$19.09$1.69B1.48718,940 shs1.61 million shsKURAKura Oncology$5.85-3.5%$6.18$5.41▼$23.48$524.64M0.41.24 million shs2.27 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+2.14%+7.40%+6.14%+23.82%+30.65%BKDBrookdale Senior Living-0.29%0.00%+3.96%+13.50%+3.25%CNTACentessa Pharmaceuticals-1.97%+0.40%-3.04%-21.08%+45.98%KURAKura Oncology-3.47%-9.16%-5.65%-25.38%-70.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORTArtivion2.5659 of 5 stars1.65.00.00.02.42.51.9BKDBrookdale Senior Living3.3296 of 5 stars2.23.00.04.92.80.00.6CNTACentessa Pharmaceuticals3.5129 of 5 stars4.52.00.00.02.03.30.6KURAKura Oncology4.3397 of 5 stars4.51.00.04.73.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 3.14Buy$32.005.62% UpsideBKDBrookdale Senior Living 2.40Hold$7.7012.82% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.89124.37% UpsideKURAKura Oncology 2.93Moderate Buy$24.50318.80% UpsideCurrent Analyst Ratings BreakdownLatest BKD, AORT, KURA, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/17/2025AORTArtivionCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025BKDBrookdale Senior LivingRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.005/6/2025AORTArtivionCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025AORTArtivionJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.005/6/2025AORTArtivionNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$388.54M3.33$0.85 per share35.60$6.59 per share4.60BKDBrookdale Senior Living$3.13B0.51$0.83 per share8.23$1.07 per share6.38CNTACentessa Pharmaceuticals$6.85M242.34N/AN/A$3.05 per share4.08KURAKura Oncology$53.88M9.40N/AN/A$5.32 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion-$13.36M-$0.50N/A60.60N/A-5.49%3.63%1.34%8/6/2025 (Estimated)BKDBrookdale Senior Living-$201.93M-$1.04N/AN/AN/A-7.52%-79.84%-3.33%8/14/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)KURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)Latest BKD, AORT, KURA, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/6/2025Q1 2025BKDBrookdale Senior Living-$0.11-$0.11N/A-$0.28$816.16 millionN/A5/5/2025Q1 2025AORTArtivion$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ABKDBrookdale Senior LivingN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion1.085.533.95BKDBrookdale Senior Living28.850.820.82CNTACentessa Pharmaceuticals0.2814.3714.37KURAKura Oncology0.028.078.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%BKDBrookdale Senior LivingN/ACNTACentessa Pharmaceuticals82.01%KURAKura OncologyN/AInsider OwnershipCompanyInsider OwnershipAORTArtivion7.60%BKDBrookdale Senior Living1.80%CNTACentessa Pharmaceuticals7.09%KURAKura Oncology6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,60042.70 million39.46 millionOptionableBKDBrookdale Senior Living36,000234.35 million230.13 millionOptionableCNTACentessa Pharmaceuticals200133.55 million124.09 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableBKD, AORT, KURA, and CNTA HeadlinesRecent News About These CompaniesKura Oncology (NASDAQ:KURA) Receives "Outperform" Rating from WedbushJune 20 at 9:16 AM | marketbeat.comKura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlookJune 15, 2025 | investing.comIs the Options Market Predicting a Spike in Kura Oncology Stock?June 12, 2025 | zacks.comKura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association CongressJune 12, 2025 | globenewswire.comLightning Round: 'Wait and see situation' with Papa John's, says Jim CramerJune 12, 2025 | msn.comCantor Fitzgerald Predicts Kura Oncology FY2026 EarningsJune 12, 2025 | americanbankingnews.comBrokers Issue Forecasts for Kura Oncology FY2026 EarningsJune 10, 2025 | marketbeat.comKura Oncology Grants Stock Options To New Hires Under Inducement PlanJune 7, 2025 | nasdaq.comKURA Stock Rises More Than 15% This Past Week: Here's WhyJune 6, 2025 | zacks.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comFDA Grants Priority Review to Ziftomenib Application in NPM1-Mutated Acute Myeloid LeukemiaJune 5, 2025 | precisionmedicineonline.comJMP Securities Reiterates "Market Outperform" Rating for Kura Oncology (NASDAQ:KURA)June 4, 2025 | marketbeat.comFDA Grants Priority Review to NDA of Ziftomenib in NPM1-Mutant AMLJune 4, 2025 | targetedonc.comTwo Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA)June 4, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)June 4, 2025 | marketbeat.comKura Oncology (NASDAQ:KURA) Shares Gap Up - What's Next?June 3, 2025 | marketbeat.comASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDAJune 3, 2025 | finance.yahoo.comASCO: Kura, Kyowa reveal 23% remission rate behind oral leukemia drug's phase 2 winJune 2, 2025 | fiercebiotech.comKura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comFDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s ZiftomenibJune 2, 2025 | insidermonkey.comSquarepoint Ops LLC Takes $799,000 Position in Kura Oncology, Inc. (NASDAQ:KURA)June 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBKD, AORT, KURA, and CNTA Company DescriptionsArtivion NYSE:AORT$30.30 +0.60 (+2.01%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$30.27 -0.03 (-0.09%) As of 06/20/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Brookdale Senior Living NYSE:BKD$6.82 -0.02 (-0.22%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$6.82 0.00 (0.00%) As of 06/20/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Centessa Pharmaceuticals NASDAQ:CNTA$12.43 -0.25 (-1.97%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$12.46 +0.03 (+0.24%) As of 06/20/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Kura Oncology NASDAQ:KURA$5.85 -0.21 (-3.47%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.92 +0.08 (+1.28%) As of 06/20/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
